## interChange Provider Important Message

## **Attention Providers:**

## Connecticut Medical Assistance Program (CMAP) Laboratory Fee Schedule and CMAP Addendum B Update

The following procedure codes were previously added to the Connecticut Medical Assistance Program (CMAPs) Laboratory fee schedule at an interim rate in absence of a set Medicare rate (Provider Bulletin 2020-71 - Addition of Procedure Codes to the Independent Laboratory Fee Schedule and CMAP Addendum B). Consistent with the guidance published in PB 2020-71, CMAP is updating the reimbursement for the following services to 100% of Medicare rates retroactive to the code's effective date. All previously submitted claims will automatically be reprocessed and adjusted accordingly.

| Procedure<br>Code | Description  | Rate     | Effective<br>Date |
|-------------------|--|----------|-------------------|
| 87426             | Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiplestep method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19]) | \$35.33  | 6/25/2020         |
| 86408             | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid19]); screen   | \$42.13  | 8/10/2020         |
| 86409             | Neutralizing antibody, severe acute respiratory syndrome coronavirus 2(sarscov-2) (coronavirus disease [covid19]); titer   | \$105.33 | 8/10/2020         |
| 87636             | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique  | \$142.63 | 10/6/2020         |



## interChange Provider Important Message

| 87637 | Infectious agent detection by nucleic acid (DNA   | \$142.63 | 10/6/2020 |
|-------|---|----------|-----------|
|       | or RNA); severe acute respiratory syndrome        |          |           |
|       | coronavirus 2 (SARS-CoV-2) (Coronavirus           |          |           |
|       | disease [COVID-19]), influenza virus types A      |          |           |
|       | and B, and respiratory syncytial virus, multiplex |          |           |
|       | amplified probe technique                         |          |           |

